查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602818

抗凝血逆转药物市场：依产品、分布 - 全球预测 2025-2030

Anticoagulant Reversal Drugs Market by Product (Andexxa, Idarucizumab, Protamine), Distribution (Hospital Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗凝血逆转药物市值为6.4638亿美元，预计2024年将达7.254亿美元，复合年增长率为12.31%，预计2030年将达到14.5759亿美元。

抗凝血逆转剂是重要的药物，用于在药物过量、紧急外科手术和失控出血等情况下抵消抗凝血剂的作用。这些药物在医疗实践中发挥重要作用，为接受抗凝血治疗的患者提供安全网并使凝血恢復正常。主要用途范围从医院急诊医学到循环系统和血液学等特定医疗部门。最终用户主要是医院、诊所和门诊手术中心。抗凝血逆转药物市场的成长是由心血管疾病盛行率上升、抗凝血治疗接受度提高、外科手术数量增加以及医疗保健安全网意识和投资不断增长等因素推动的。最新的商机在于开发更快、更有效的抗逆流药物，鑑于医疗紧急情况的快速发展，这可以提供竞争优势。与提高这些药物的疗效和安全性相关的研究投资也至关重要，特别是透过精准医疗为个别患者需求量身订做解决方案。然而，市场面临重大挑战，包括高昂的药物开发成本、严格的监管监督以及逆转药物可能导致併发症的潜在副作用。此外，新兴市场的知名度和准入有限也可能阻碍市场扩张。市场竞争非常激烈，领先的公司都专注于研发，以提供创新的解决方案并扩大产品系列。一些最好的创新领域包括开髮长效逆转药物、最大限度地减少副作用以及探索将人工智慧整合到个人化治疗计划的预测分析中。市场的动态本质要求相关人员能够适应技术进步和监管变化。市场参与企业应注重策略伙伴关係和联盟，以丰富其产品种类，开拓开拓的市场，并确保可持续的长期成长。

主要市场统计
基准年[2023] 64638万美元
预测年份 [2024] 7.254 亿美元
预测年份 [2030] 1,457.59 百万美元
复合年增长率（%） 12.31%

市场动态：快速发展的抗凝血逆转药物市场的关键市场洞察

供需的动态交互作用正在改变抗凝血逆转药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 出血性疾病和抗凝血治疗的盛行率增加
    • 全球产品核可增加
    • 计划外手术增加
  • 市场限制因素
    • 专利药高成本
  • 市场机会
    • 完善全球报销政策
    • 继续进行研究工作并提供资金来治疗抗凝血相关出血
  • 市场挑战
    • 由于重新启动抗凝血治疗存在严重风险，需要进行严格的监管改革

波特五力：驾驭抗凝血逆转市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗凝血逆转药物市场的外部影响

外部宏观环境因素在塑造抗凝血逆转药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗凝血逆转药物市场竞争状况

抗凝血逆转药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵抗凝血逆转药物市场供应商绩效评估

FPNV定位矩阵是评估抗凝血逆转药物市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议描绘抗凝血逆转药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，抗凝血逆转药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 出血性疾病和抗凝血治疗的盛行率增加
      • 全球产品核可数量增加
      • 计划外手术增加
    • 抑制因素
      • 专利药高成本
    • 机会
      • 完善全球报销政策
      • 抗凝血相关出血治疗的持续研究与资助
    • 任务
      • 与抗凝血逆转相关的重大风险需要严格的监管改革
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章抗凝血逆转药物市场：副产品

  • 安德克萨
  • 伊达赛珠单抗
  • 鱼精蛋白
  • 氨甲环酸
  • 维生素K

第七章 抗凝血逆转药物市场经销商

  • 医院药房
  • 零售药房

第八章美洲抗凝血逆转药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太抗凝血逆转药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲抗凝血逆转药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alexion Pharmaceuticals Inc.
  • AMAG Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies, Inc.
  • BioVascular Inc.
  • Boehringer Ingelheim GmbH
  • Cadila Healthcare Limited
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Dr Reddy's Laboratories Ltd,
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Genentech, Inc.
  • Hikma Pharmaceuticals PLC
  • Octapharma AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
Product Code: MRR-035DA3C636BB

The Anticoagulant Reversal Drugs Market was valued at USD 646.38 million in 2023, expected to reach USD 725.40 million in 2024, and is projected to grow at a CAGR of 12.31%, to USD 1,457.59 million by 2030.

Anticoagulant reversal drugs are crucial medications used to counteract the effects of anticoagulants in situations such as overdosage, urgent surgical procedures, or uncontrolled bleeding. These drugs serve an essential role in medical settings, providing a safety net for patients undergoing anticoagulant therapy by quickly restoring normal blood clotting. The main applications span from emergency care in hospitals to specific medical departments like cardiology and hematology. End-users primarily include hospitals, clinics, and ambulatory surgical centers. Market growth for anticoagulant reversal drugs is driven by factors such as the rising incidence of cardiovascular diseases, increasing acceptance of anticoagulation therapy, a growing number of surgical procedures, and heightened awareness and investment in healthcare safety nets. Latest opportunities lie in developing more rapid and effective reversal agents, which could provide competitive advantages given the fast-paced nature of medical emergencies. Investment in research related to improving the efficacy and safety profile of these drugs is also crucial, particularly in customizing solutions for individual patient needs through precision medicine. However, the market faces significant challenges, including high drug development costs, stringent regulatory scrutiny, and potential side effects of reversal agents that can lead to complications. Additionally, limited awareness and access in developing regions may hinder market expansion. The market is highly competitive, with major players focusing on R&D to offer innovative solutions and expand their product portfolios. The best innovation areas include developing longer-acting reversal agents, minimizing adverse effects, and exploring the integration of AI in predictive analytics for personalized treatment plans. The nature of the market is dynamic and demands adaptability from stakeholders to stay abreast of technological advancements and regulatory changes. Market participants should focus on strategic partnerships and collaborations to enhance product offerings and tap into untapped markets, ensuring sustainable and long-term growth.

KEY MARKET STATISTICS
Base Year [2023] USD 646.38 million
Estimated Year [2024] USD 725.40 million
Forecast Year [2030] USD 1,457.59 million
CAGR (%) 12.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anticoagulant Reversal Drugs Market

The Anticoagulant Reversal Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of bleeding disorders and anticoagulant therapies
    • Growing number of product approvals worldwide
    • Increasing incidence of unplanned surgeries
  • Market Restraints
    • High cost of the patent drugs
  • Market Opportunities
    • Improvements in reimbursement policies globally
    • Ongoing research activities and funding to treat anticoagulant-related bleeds
  • Market Challenges
    • Stringent regulatory reforms due to severe risks associated with the reversal of anticoagulation

Porter's Five Forces: A Strategic Tool for Navigating the Anticoagulant Reversal Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anticoagulant Reversal Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anticoagulant Reversal Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anticoagulant Reversal Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anticoagulant Reversal Drugs Market

A detailed market share analysis in the Anticoagulant Reversal Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anticoagulant Reversal Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anticoagulant Reversal Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anticoagulant Reversal Drugs Market

A strategic analysis of the Anticoagulant Reversal Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anticoagulant Reversal Drugs Market, highlighting leading vendors and their innovative profiles. These include Alexion Pharmaceuticals Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., AstraZeneca PLC, Bausch Health Companies, Inc., BioVascular Inc., Boehringer Ingelheim GmbH, Cadila Healthcare Limited, CSL Limited, Daiichi Sankyo Company, Limited, Dr Reddy's Laboratories Ltd,, Eli Lilly and Company, Fresenius Kabi AG, Genentech, Inc., Hikma Pharmaceuticals PLC, Octapharma AG, Otsuka Pharmaceutical Co., Ltd., and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the Anticoagulant Reversal Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Andexxa, Idarucizumab, Protamine, Tranexamic Acid, and Vitamin K.
  • Based on Distribution, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of bleeding disorders and anticoagulant therapies
      • 5.1.1.2. Growing number of product approvals worldwide
      • 5.1.1.3. Increasing incidence of unplanned surgeries
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the patent drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements in reimbursement policies globally
      • 5.1.3.2. Ongoing research activities and funding to treat anticoagulant-related bleeds
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory reforms due to severe risks associated with the reversal of anticoagulation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anticoagulant Reversal Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Andexxa
  • 6.3. Idarucizumab
  • 6.4. Protamine
  • 6.5. Tranexamic Acid
  • 6.6. Vitamin K

7. Anticoagulant Reversal Drugs Market, by Distribution

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail Pharmacies

8. Americas Anticoagulant Reversal Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anticoagulant Reversal Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anticoagulant Reversal Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alexion Pharmaceuticals Inc.
  • 2. AMAG Pharmaceuticals, Inc.
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. AstraZeneca PLC
  • 5. Bausch Health Companies, Inc.
  • 6. BioVascular Inc.
  • 7. Boehringer Ingelheim GmbH
  • 8. Cadila Healthcare Limited
  • 9. CSL Limited
  • 10. Daiichi Sankyo Company, Limited
  • 11. Dr Reddy's Laboratories Ltd,
  • 12. Eli Lilly and Company
  • 13. Fresenius Kabi AG
  • 14. Genentech, Inc.
  • 15. Hikma Pharmaceuticals PLC
  • 16. Octapharma AG
  • 17. Otsuka Pharmaceutical Co., Ltd.
  • 18. Pfizer, Inc.

LIST OF FIGURES

  • FIGURE 1. ANTICOAGULANT REVERSAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTICOAGULANT REVERSAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTICOAGULANT REVERSAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTICOAGULANT REVERSAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTICOAGULANT REVERSAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY ANDEXXA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY IDARUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PROTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY TRANEXAMIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY VITAMIN K, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. ANTICOAGULANT REVERSAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. ANTICOAGULANT REVERSAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023